Show simple item record

dc.contributor.advisorMarjanović, Goran
dc.contributor.otherMačukanović-Golubović, Lana
dc.contributor.otherJevtović-Stoimenov, Tatjana
dc.contributor.otherMihaljević, Biljana
dc.creatorSimonović, Olivera B.
dc.date.accessioned2018-12-26T13:30:17Z
dc.date.available2018-12-26T13:30:17Z
dc.date.available2020-07-03T16:07:38Z
dc.date.issued2018-02-27
dc.identifier.urihttp://nardus.mpn.gov.rs/handle/123456789/10453
dc.identifier.urihttp://eteze.ni.ac.rs/application/showtheses?thesesId=5832
dc.identifier.urihttps://fedorani.ni.ac.rs/fedora/get/o:1478/bdef:Content/download
dc.identifier.urihttp://vbs.rs/scripts/cobiss?command=DISPLAY&base=70052&RID=1025977325
dc.description.abstractIn classical Hodgkin’s lymphoma (cHL) the existing prognostic scoring systems do not include markers that adequately reflect the interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells and tumor environment. The research objective is to determine the relationship between serum Galectin-1 (Gal-1) and soluble CD163 (sCD163) and the clinical status of patients with cHL, with special emphasis on the presence of relapse, progression, or resistance to the therapy applied. The research included 79 patients. Of this number, 63 were patients with cHL, and the control group consisted of 16 healthy volunteers. The study group of 63 patients with cHL included a subgroup of newly diagnosed patients without therapy, newly diagnosed patients with therapy, patients with relapse and progression of the disease, and primary refractory patients during 2014 and 2015. Analysis of the levels of sCD163 and sGal-1 within a group of patients suffering from cHL has shown that the values of both molecules were higher in relapsed patients and the subgroup with progressive disease comparing the subgroup of newly diagnosed patients without therapy or patients with therapy onset. Determination of Gal-1 and sCD163 levels is simple and reliable analysis that can contribute to the identification of high-risk patients with cHL, and deserves inclusion in current prognostic scoring systems.en
dc.formatapplication/pdf
dc.languagesr
dc.publisherУниверзитет у Нишу, Медицински факултетsr
dc.rightsopenAccessen
dc.sourceУниверзитет у Нишуsr
dc.subjectHoĉkinov limfomsr
dc.subjectHodgkin’s lymphomaen
dc.subjectInternacionalni prognostiĉki skorsr
dc.subjectsCD163sr
dc.subjectGal-1sr
dc.subjectInternational prognostic scoreen
dc.subjectGal-1en
dc.subjectsCD163en
dc.titleZnačaj galektina-1 kao prognostičkog faktora u lečenju klasičnog Hočkinovog limfomasr
dc.typedoctoralThesis
dc.rights.licenseBY-NC-ND
dc.identifier.fulltexthttp://nardus.mpn.gov.rs/bitstream/id/53294/Disertacija.pdf
dc.identifier.fulltexthttp://nardus.mpn.gov.rs/bitstream/id/53295/Simonovic_Olivera_B.pdf


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record